Drug*placebo interaction effect may bias clinical trials interpretation: hybrid balanced placebo and randomized placebo-controlled design

被引:8
|
作者
Hammami, Muhammad M. [1 ,2 ]
Hammami, Safa [1 ]
Al-Swayeh, Reem [1 ]
Al-Gaai, Eman [1 ]
Farah, Faduma Abdi [1 ]
De Padua, Sophia J. S. [1 ]
机构
[1] King Faisal Specialist Hosp & Res Ctr, Dept Clin Studies & Empir Eth, POB 3354,MBC 03, Riyadh 11211, Saudi Arabia
[2] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia
来源
BMC MEDICAL RESEARCH METHODOLOGY | 2016年 / 16卷
关键词
Balanced placebo design; Randomized placebo-controlled trials; Biased drug effect size; Drug placebo interaction; Effect modification;
D O I
10.1186/s12874-016-0269-1
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Conventional randomized placebo-controlled study design assumes the absence of drug*placebo interaction. We hypothesized the presence of such an interaction and that conventionally estimated drug effect might be biased. The objectives of the study were to determine the drug*placebo interaction effect (main) and compare conventionally estimated and interaction model-estimated drug effects (secondary). Methods: We used a hybrid of balanced placebo and randomized placebo-controlled designs. Four hundred eighty healthy volunteers were randomized to three groups. The first received hydroxyzine (25 mg) described as hydroxyzine or placebo, the second received placebo described as hydroxyzine or placebo, and the third received hydroxyzine and placebo described as unknown; each in a randomized crossover design. Seven participants failed to crossover. Group assignment was concealed from participants and study coordinators. Coordinators were blinded to group and intervention assignment. Participants and coordinators were deceived as to study objectives. Main outcomes were mean area-under-the-curve of drowsiness (therapeutic outcome) and mouth-dryness (adverse outcome), self-reported on 100 mm visual analog scale over 7 h. Drug, placebo, placebo + interaction, and total effects were estimated using analysis of covariance by comparing received hydroxyzine/told placebo to received placebo/told placebo, received placebo/told hydroxyzine to received placebo/told placebo, received hydroxyzine/told hydroxyzine to received hydroxyzine/told placebo, and received hydroxyzine/told hydroxyzine to received placebo/told placebo, respectively. Drug effect was also conventionally estimated in the third group. Results: Mean (SD) age was 31.4 (6.6) years, 65% were males. There was significant difference between placebo + interaction effect and placebo effect for both drowsiness and mouth-dryness with a mean difference (95% confidence interval) of 35.1 (5.6 to 64.6) and 23.8 (2.4 to 45.2) mm*hr, respectively. Total effect was larger than the sum of drug and placebo effects for drowsiness (139.7 (109.8 to 169.6) vs. 99.1 (68.2 to 130.0) mm*hr) and mouth-dryness (63.6 (41.1 to 86.1) vs. 34.7 (11.1 to 58.4) mm*hr). Conventionally estimated drug effect was larger than interaction model-estimated drug effect for drowsiness (69.2 (45.5 to 92.8) vs. (58.3 (31.6 to 85.0) mm*hr) and mouth-dryness (19.9 (5.3 to 34.5) vs. 9.5 (-9.2 to 28.1) mm*hr). Conclusions: There is significant and important drug*placebo interaction effect that may bias conventionally estimated drug effect.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Building in placebo-controlled trials
    Ehrlich, GE
    ANNALS OF INTERNAL MEDICINE, 2001, 134 (12) : 1150 - 1151
  • [32] THE ETHICS OF PLACEBO-CONTROLLED TRIALS
    STREINER, DL
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1995, 40 (04): : 165 - 166
  • [33] Placebo-controlled trials - Response
    Temple, R
    Ellenberg, SS
    ANNALS OF INTERNAL MEDICINE, 2001, 135 (01) : 63 - 64
  • [34] The ethics of placebo-controlled trials
    Reynolds, T
    ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) : 491 - 492
  • [35] MOCLOBEMIDE - PLACEBO-CONTROLLED TRIALS
    SILVERSTONE, T
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1993, 7 (3-4) : 133 - 136
  • [36] Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis
    Sansone, Valeria A.
    Burge, James
    McDermott, Michael P.
    Smith, Patty C.
    Herr, Barbara
    Tawil, Rabi
    Pandya, Shree
    Kissel, John
    Ciafaloni, Emma
    Shieh, Perry
    Ralph, Jeffrey W.
    Amato, Antony
    Cannon, Steve C.
    Trivedi, Jaya
    Barohn, Richard
    Crum, Brian
    Mitsumoto, Hiroshi
    Pestronk, Alan
    Meola, Giovanni
    Conwit, Robin
    Hanna, Michael G.
    Griggs, Robert C.
    NEUROLOGY, 2016, 86 (15) : 1408 - 1416
  • [37] What is controlled for in placebo-controlled trials?
    Fillingim, RB
    Price, DD
    MAYO CLINIC PROCEEDINGS, 2005, 80 (09) : 1119 - 1121
  • [38] The place of placebo? The ethics of placebo-controlled trials in bipolar disorder
    Berk, Michael
    ACTA NEUROPSYCHIATRICA, 2007, 19 (02): : 74 - 75
  • [40] Estimation of placebo effect in randomized placebo-controlled trials for moderate or severe vasomotor symptoms: a meta-analysis
    Zhou, Tianyu
    MENOPAUSE-THE JOURNAL OF THE MENOPAUSE SOCIETY, 2023, 30 (01): : 5 - 10